LIVIVO - Search results -

Search results

Result 1 - 10 of total 57

Search options

Article: The development and function of the skeleton and bone metastases.

Rodan, Gideon A

2003 Volume 97, Issue 3 Suppl, Page(s) 726–732

Abstract: Bone is a frequent site of metastases of the most common tumors, e.g., breast carcinoma and prostate carcinoma. The functions of the skeleton, calcium homeostasis and mechanical support, are carried out by the continuous destruction and rebuilding of ... ...

Abstract	Bone is a frequent site of metastases of the most common tumors, e.g., breast carcinoma and prostate carcinoma. The functions of the skeleton, calcium homeostasis and mechanical support, are carried out by the continuous destruction and rebuilding of small packets of this tissue called bone remodeling. Multinucleated, hemopoietically derived osteoclasts, which are related to macrophages, digest the bone, and mesenchymal-derived osteoblasts rebuild it. This process is kept in balance by finely regulated processes whereby osteoblast lineage cells respond to homeostatic signals and release factors that regulate osteoclast generation and activity. Cells that participate in inflammation and immunity also can stimulate osteoclast formation and lead to bone destruction. Tumor cells most likely subvert these physiologic processes to lodge in bone and cause metastases.
MeSH term(s)	Bone Neoplasms/physiopathology ; Bone Neoplasms/secondary ; Bone Remodeling/physiology ; Bone and Bones/embryology ; Bone and Bones/physiology ; Breast Neoplasms/pathology ; Female ; Humans ; Male ; Osteoblasts/cytology ; Osteoblasts/physiology ; Osteoclasts/cytology ; Osteoclasts/physiology ; Parathyroid Hormone/physiology ; Prostatic Neoplasms/pathology
Chemical Substances	Parathyroid Hormone
Language	English
Publishing date	2003-02-01
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.11147
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Bisphosphonates and primary hyperparathyroidism.

Rodan, Gideon A

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

2002 Volume 17 Suppl 2, Page(s) N150–3

Abstract: Bisphosphonates (BP) are pyrophosphate analogs that include very potent inhibitors of bone resorption. BPs act directly on the osteoclast, suppressing isoprenylation by inhibiting farnesyl diphosphate synthase in the cholesterol pathway, which causes ... ...

Abstract	Bisphosphonates (BP) are pyrophosphate analogs that include very potent inhibitors of bone resorption. BPs act directly on the osteoclast, suppressing isoprenylation by inhibiting farnesyl diphosphate synthase in the cholesterol pathway, which causes osteoclast inactivation. BPs should therefore reduce the bone loss produced by any cause, including hyperparathyroidism and hypercalcemia of malignancy (MIH), caused by parathyroid hormone (PTH) and PTH-related protein (PTHrP), respectively. BPs at higher doses than used in osteoporosis are indeed the treatment of choice for malignancy-induced hypercalcemia. Limited, but convincing, data show that BPs at doses effective in osteoporosis also reverse bone loss associated with mild primary hyperparathyroidism (PHPT).
MeSH term(s)	Alkyl and Aryl Transferases/antagonists & inhibitors ; Alkyl and Aryl Transferases/metabolism ; Bone Resorption/metabolism ; Carcinoma/drug therapy ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Geranyltranstransferase ; Humans ; Hypercalcemia/drug therapy ; Hypercalcemia/etiology ; Hyperparathyroidism/complications ; Hyperparathyroidism/drug therapy ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Osteoporosis/drug therapy ; Parathyroid Hormone/physiology ; Parathyroid Hormone-Related Protein ; Parathyroid Neoplasms/drug therapy ; Peptide Hormones/antagonists & inhibitors ; Peptide Hormones/metabolism
Chemical Substances	Diphosphonates ; PTHLH protein, human ; Parathyroid Hormone ; Parathyroid Hormone-Related Protein ; Peptide Hormones ; Alkyl and Aryl Transferases (EC 2.5.-) ; Geranyltranstransferase (EC 2.5.1.10)
Language	English
Publishing date	2002-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	632783-7
ISSN	1523-4681 ; 0884-0431
ISSN (online)	1523-4681
ISSN	0884-0431
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mechanism of action of bisphosphonates.

Reszka, Alfred A / Rodan, Gideon A

Current osteoporosis reports

2005 Volume 1, Issue 2, Page(s) 45–52

Abstract: In recent years, substantial progress has been made in understanding the mechanism for bisphosphonate suppression of bone turnover. Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action. Simple ... ...

Abstract	In recent years, substantial progress has been made in understanding the mechanism for bisphosphonate suppression of bone turnover. Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action. Simple bisphosphonates such as clodronate and etidronate inhibit bone resorption through induction of osteoclast apoptosis. Clodronate, and perhaps etidronate, triggers apoptosis by generating a toxic analog of adenosine triphosphate, which then targets the mitochondria, the energy center within the cell. For nitrogen-containing bisphosphonates, the direct intracellular target is the enzyme farnesyl diphosphate synthase in the cholesterol biosynthetic pathway. Its inhibition suppresses a process called protein geranylgeranylation, which is essential for the basic cellular processes required for osteoclastic bone resorption. Although nitrogen-containing bisphosphonates can induce osteoclast apoptosis, this is not necessary for their inhibition of bone resorption.
MeSH term(s)	Bone Resorption/prevention & control ; Clodronic Acid/chemistry ; Clodronic Acid/therapeutic use ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Etidronic Acid/chemistry ; Etidronic Acid/therapeutic use ; Humans ; Osteoporosis/prevention & control ; Sensitivity and Specificity ; Structure-Activity Relationship
Chemical Substances	Diphosphonates ; Clodronic Acid (0813BZ6866) ; Etidronic Acid (M2F465ROXU)
Language	English
Publishing date	2005-07-15
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Review
ZDB-ID	2186581-4
ISSN	1544-1873
ISSN	1544-1873
DOI	10.1007/s11914-003-0008-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Osteoporosis and bisphosphonates.

Rodan, Gideon A / Reszka, Alfred A

The Journal of bone and joint surgery. American volume

2003 Volume 85-A Suppl 3, Page(s) 8–12

MeSH term(s)	Aged ; Bone Density/drug effects ; Bone Density/physiology ; Bone Remodeling/drug effects ; Bone Remodeling/physiology ; Diphosphonates/adverse effects ; Diphosphonates/chemistry ; Diphosphonates/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Osteoclasts/drug effects ; Osteoclasts/physiology ; Osteoporosis/drug therapy ; Osteoporosis/physiopathology ; Osteoporosis, Postmenopausal/drug therapy ; Osteoporosis, Postmenopausal/physiopathology ; Structure-Activity Relationship
Chemical Substances	Diphosphonates
Language	English
Publishing date	2003-08-13
Publishing country	United States
Document type	Lecture
ZDB-ID	220625-0
ISSN	1535-1386 ; 0021-9355
ISSN (online)	1535-1386
ISSN	0021-9355
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.58/1: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 464: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Nitrogen-containing bisphosphonate mechanism of action.

Reszka, Alfred A / Rodan, Gideon A

Mini reviews in medicinal chemistry

2004 Volume 4, Issue 7, Page(s) 711–719

Abstract: The current paradigm for drug discovery requires the identification of a target involved in the disease process (e.g. enzyme or receptor) and the development of an appropriate ligand (activator, inhibitor or selective modulator). Selection of ligands for ...

Abstract	The current paradigm for drug discovery requires the identification of a target involved in the disease process (e.g. enzyme or receptor) and the development of an appropriate ligand (activator, inhibitor or selective modulator). Selection of ligands for clinical development is based on the therapeutic window between efficacy vs. safety and ADME (absorption, distribution, metabolism and elimination) considerations. For bisphosphonates (BPs) the process has not followed that paradigm. BPs have very low absorption and are retained in bone, their target tissue. A few have been used on a limited basis for over 20 years in diseases of rapid bone destruction (e.g. post-menopausal osteoporosis, Paget's disease, bone metastases, etc.), without understanding their molecular mechanism of action. The nitrogen-containing BPs (N-BPs) are the latest and most potent addition to this family of compounds and have the widest use. They have high potency, are specifically targeted to the osteoclast on bone and are used at very low doses (5-10 mg clinically). Over the last four years, there was significant progress in elucidating the mechanism of action of BPs, both lacking and containing nitrogen. This review will focus on the mechanism of action of the N-BPs, specifically alendronate (ALN) and risedronate (RIS), the two agents most widely used. For these and all other N-BPs, the molecular target is the isoprenoid biosynthetic enzyme, farnesyl diphosphate synthase, in the cholesterol biosynthesis pathway. Although inhibition of this enzyme by N-BPs results in the suppression of sterol biosynthesis, it is actually disruption of a branch pathway, isoprenylation, that is responsible for N-BP pharmacological activity. Isoprenylation involves covalent linkage of the 15 or 20 carbon isoprene moiety farnesyl diphosphate or geranylgeranyl diphosphate, respectively, to the carboxy-terminus of regulatory proteins, including the small GTPases Ras, Rac, Rho and Cdc42. The latter three, as well as numerous others, are geranylgeranylated and play a rate-limiting role in the activity of the bone-resorbing osteoclast. This targeted osteoclast inhibition accounts for the potency of the N-BPs and for their ability to elicit the desired therapeutic response of suppressing bone turnover. The occasional gastrointestinal irritation caused by N-BPs appears to be mechanism-based and is also briefly reviewed.
MeSH term(s)	Alkyl and Aryl Transferases/antagonists & inhibitors ; Animals ; Bone Resorption/drug therapy ; Bone Resorption/enzymology ; Bone Resorption/metabolism ; Cholesterol/biosynthesis ; Diphosphonates/adverse effects ; Diphosphonates/chemistry ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Geranyltranstransferase ; Humans ; Molecular Structure ; Nitrogen/chemistry ; Osteoclasts/drug effects ; Osteoclasts/enzymology ; Osteoclasts/metabolism ; Protein Prenylation/drug effects
Chemical Substances	Diphosphonates ; Cholesterol (97C5T2UQ7J) ; Alkyl and Aryl Transferases (EC 2.5.-) ; Geranyltranstransferase (EC 2.5.1.10) ; Nitrogen (N762921K75)
Language	English
Publishing date	2004-09
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2104081-3
ISSN	1875-5607 ; 1389-5575
ISSN (online)	1875-5607
ISSN	1389-5575
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5891: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Control of osteoblast function and regulation of bone mass.

Harada, Shun-ichi / Rodan, Gideon A

Nature

2003 Volume 423, Issue 6937, Page(s) 349–355

Abstract: The skeleton is an efficient 'servo' (feedback-controlled/steady-state) system that continuously integrates signals and responses which sustain its functions of delivering calcium while maintaining strength. In many individuals, bone mass homeostasis ... ...

Abstract	The skeleton is an efficient 'servo' (feedback-controlled/steady-state) system that continuously integrates signals and responses which sustain its functions of delivering calcium while maintaining strength. In many individuals, bone mass homeostasis starts failing in midlife, leading to bone loss, osteoporosis and debilitating fractures. Recent advances, spearheaded by genetic information, offer the opportunity to stop or reverse this downhill course.
MeSH term(s)	Bone Development/genetics ; Bone and Bones/cytology ; Bone and Bones/physiology ; Homeostasis ; Humans ; Organ Size ; Osteoblasts/cytology ; Osteoblasts/physiology ; Signal Transduction ; Transcription, Genetic
Language	English
Publishing date	2003-05-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	120714-3
ISSN	1476-4687 ; 0028-0836
ISSN (online)	1476-4687
ISSN	0028-0836
DOI	10.1038/nature01660
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 26: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 9: Show issues
Zs.MO 244: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Bisphosphonate mechanism of action.

Reszka, Alfred A / Rodan, Gideon A

Current rheumatology reports

2003 Volume 5, Issue 1, Page(s) 65–74

Abstract: The nitrogen-containing bisphosphonates (N-BPs), alendronate and risedronate, are the only pharmacologic agents shown to prevent spine and nonvertebral fractures associated with postmenopausal and glucocorticoid-induced osteoporosis. At the tissue level, ...

Abstract	The nitrogen-containing bisphosphonates (N-BPs), alendronate and risedronate, are the only pharmacologic agents shown to prevent spine and nonvertebral fractures associated with postmenopausal and glucocorticoid-induced osteoporosis. At the tissue level, this is achieved through osteoclast inhibition, which leads to reduced bone turnover, increased bone mass, and improved mineralization. The molecular targets of bisphosphonates (BPs) have recently been identified. This review will discuss the mechanism of action of BPs, focusing on alendronate and risedronate, which are the two agents most widely studied. They act on the cholesterol biosynthesis pathway enzyme, farnesyl diphosphate synthase. By inhibiting this enzyme in the osteoclast, they interfere with geranylgeranylation (attachment of the lipid to regulatory proteins), which causes osteoclast inactivation. This mechanism is responsible for N-BP suppression of osteoclastic bone resorption and reduction of bone turnover, which leads to fracture prevention.
MeSH term(s)	Apoptosis ; Bone Resorption/metabolism ; Diphosphonates/chemistry ; Diphosphonates/metabolism ; Diphosphonates/pharmacology ; Humans ; Mevalonic Acid/antagonists & inhibitors ; Osteoclasts/drug effects ; Osteoclasts/metabolism ; Osteoclasts/physiology ; Osteoporosis/metabolism
Chemical Substances	Diphosphonates ; Mevalonic Acid (S5UOB36OCZ)
Language	English
Publishing date	2003-02-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057357-1
ISSN	1523-3774
ISSN	1523-3774
DOI	10.1007/s11926-003-0085-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Pathogenesis of osteoporosis.

Raisz, Lawrence G / Rodan, Gideon A

Endocrinology and metabolism clinics of North America

2003 Volume 32, Issue 1, Page(s) 15–24

Abstract: There are many pathways that might lead to decreased bone mass, skeletal fragility, and increased fracture risk in osteoporosis. Some of these have been clearly identified, such as estrogen deficiency. Others that were conceived on the basis of ... ...

Abstract	There are many pathways that might lead to decreased bone mass, skeletal fragility, and increased fracture risk in osteoporosis. Some of these have been clearly identified, such as estrogen deficiency. Others that were conceived on the basis of experimental findings and recent scientific discoveries such as abnormalities of cytokines, bone growth factors, and osteoblast transcription factors remain interesting but speculative. The recent revolution in genomics and proteomics opens new avenues for pursuing in great depth the pathways leading to osteoporosis. Animal models developed largely in rodents can suggest specific factors that can be further studied in primate models and in osteoporotic patients. Identification of specific pathogenetic mechanisms should lead to new approaches to the diagnosis and management of this disorder.
MeSH term(s)	Animals ; Bone Remodeling/physiology ; Bone and Bones/pathology ; Fractures, Bone/epidemiology ; Humans ; Osteoporosis/etiology ; Osteoporosis/pathology ; Risk Factors
Language	English
Publishing date	2003-03-26
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	92116-6
ISSN	1558-4410 ; 0889-8529
ISSN (online)	1558-4410
ISSN	0889-8529
DOI	10.1016/s0889-8529(02)00055-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 148: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Involvement of alpha(v)beta3 integrins in osteoclast function.

Nakamura, Ichiro / Duong, Le T / Rodan, Sevgi B / Rodan, Gideon A

Journal of bone and mineral metabolism

2007 Volume 25, Issue 6, Page(s) 337–344

Abstract: Integrins are heterodimeric adhesion receptors that mediate cell-matrix interaction. Osteoclast exhibits high expression of the alpha(v)beta(3) integrin, which binds to a variety of extracellular matrix proteins including vitronectin, osteopontin, and ... ...

Abstract	Integrins are heterodimeric adhesion receptors that mediate cell-matrix interaction. Osteoclast exhibits high expression of the alpha(v)beta(3) integrin, which binds to a variety of extracellular matrix proteins including vitronectin, osteopontin, and bone sialoprotein. Arg-Gly-Asp (RGD)-containing peptides, RGD-mimetics, and blocking antibodies to alpha(v)beta(3) integrin were shown to inhibit bone resorption in vitro and in vivo, suggesting that this integrin may play an important role in regulating osteoclast function. Several lines of evidence have demonstrated that a number of signaling molecules are involved in the alpha(v)beta(3) integrin-dependent signaling pathway, including c-Src, Pyk2, c-Cbl, and p130(Cas). In this article, we review the history of "alpha(v)beta(3) integrin and osteoclasts" and discuss the involvement of alpha(v)beta(3) integrins in osteoclast function at tissue, cellular, and molecular levels. A better understanding of the role of alpha(v)beta(3) integrin in osteoclastic bone resorption would provide opportunities for developing new therapeutics to treat human bone diseases, including rheumatoid arthritis, osteoporosis, and periodontal disease.
MeSH term(s)	Animals ; Bone Diseases/therapy ; Humans ; Integrin alphaVbeta3/metabolism ; Osteoclasts/cytology ; Osteoclasts/metabolism ; Receptor Cross-Talk ; Signal Transduction
Chemical Substances	Integrin alphaVbeta3
Language	English
Publishing date	2007-10-25
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	1295123-7
ISSN	1435-5604 ; 0914-8779
ISSN (online)	1435-5604
ISSN	0914-8779
DOI	10.1007/s00774-007-0773-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4894: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Bisphosphonate mechanism of action.

Rodan, Gideon A / Reszka, Alfred A

Current molecular medicine

2002 Volume 2, Issue 6, Page(s) 571–577

Abstract: Nitrogen-containing bisphosphonates (N-BPs) are potent inhibitors of bone resorption widely used in the treatment of osteoporosis and other bone degrading disorders. At the tissue level, N-BPs reduce bone turnover, increase bone mass and mineralization, ... ...

Abstract	Nitrogen-containing bisphosphonates (N-BPs) are potent inhibitors of bone resorption widely used in the treatment of osteoporosis and other bone degrading disorders. At the tissue level, N-BPs reduce bone turnover, increase bone mass and mineralization, measured clinically as a rise in bone mineral density, increase bone strength and reduce fracture risk. At the cellular level, N-BPs, localize preferentially at sites of bone resorption, where mineral is exposed, are taken up by ostoclasts and inhibit osteoclast activity. The bone formation that follows incroporates the N-BP in the matrix, where it becomes pharmacologically inactive until released at a future time during bone remodeling. At the molecular level, N-BPs inhibit an enzyme in the cholesterol synthesis pathway, farnesyl diphosphate synthase. As a result, there is a reduction in the lipid geranylgeranyl diphosphate, which prenylates GTPases required for cytoskeletal organization and vesicular traffic in the osteoclast, leading to osteoclast inactivation.
MeSH term(s)	Alendronate/metabolism ; Animals ; Bone Resorption ; Cholesterol/metabolism ; Cytoskeleton/metabolism ; Diphosphonates/chemistry ; Diphosphonates/metabolism ; Diterpenes ; Humans ; Lipid Metabolism ; Models, Biological ; Nitrogen/metabolism ; Osteoclasts/metabolism ; Polyisoprenyl Phosphates/metabolism ; Protein Prenylation
Chemical Substances	Diphosphonates ; Diterpenes ; Polyisoprenyl Phosphates ; Cholesterol (97C5T2UQ7J) ; geranylgeranyl pyrophosphate (N21T0D88LX) ; Nitrogen (N762921K75) ; Alendronate (X1J18R4W8P)
Language	English
Publishing date	2002-09
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2064873-X
ISSN	1566-5240
ISSN	1566-5240
DOI	10.2174/1566524023362104
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5580: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito